Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Guardant Health (GH) and PTC Therapeutics (PTCT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB – Research Report), Guardant Health (GH – Research Report) and PTC Therapeutics (PTCT – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biogen (BIIB)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Biogen today and set a price target of $190.00. The company’s shares closed last Thursday at $192.08.
According to TipRanks.com, Flynn is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $205.30 average price target, representing a 6.1% upside. In a report released yesterday, Barclays also initiated coverage with a Hold rating on the stock with a $185.00 price target.
See today’s best-performing stocks on TipRanks >>
Guardant Health (GH)
Wells Fargo analyst Brandon Couillard maintained a Buy rating on Guardant Health today and set a price target of $125.00. The company’s shares closed last Thursday at $106.38.
According to TipRanks.com, Couillard is a 5-star analyst with an average return of
Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $131.18, which is a 23.0% upside from current levels. In a report issued on February 17, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $120.00 price target.
PTC Therapeutics (PTCT)
In a report released yesterday, Geoff Meacham from Citi maintained a Hold rating on PTC Therapeutics, with a price target of $75.00. The company’s shares closed last Thursday at $69.90.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PTC Therapeutics with a $89.33 average price target, a 30.3% upside from current levels. In a report issued on February 12, TD Cowen also maintained a Hold rating on the stock with a $75.00 price target.
